Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Drug Resistant Epilepsy × Sirolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Hematologic Neoplasms 6 Leukemia, Myeloid, Acute 4 Tuberous Sclerosis 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Epilepsy 3 Recurrence 2 Myeloproliferative Disorders 2 Myelodysplastic Syndromes 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Bronchiolitis Obliterans Syndrome 2 Thyroid Neoplasms 1 Sarcoma 1 Prostate Cancer Recurrent 1 Primary Myelofibrosis 1 Non-Malignant Neoplasm 1 Neoplasms 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, T-Cell 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lymphoma 1 Lymphangioleiomyomatosis 1 Leukemia, Prolymphocytic 1 Leukemia, Plasma Cell 1 Leukemia, Myeloid 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Monocytic, Acute 1

Interventions

Sirolimus 1 Diet, Ketogenic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05534672 2023-08-08

RaRE-TS

Children's Memorial Health Institute, Poland

Phase 3 Recruiting

Drug Resistant Epilepsy, Epilepsy, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡